Business Context and Reporting Period
Company: BGM Group Ltd. (formerly Qilian International Holding Group Limited)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended September 30, 2024
Corporate Structure: BGM is a Cayman Islands holding company with no material operations. It conducts business in China through a Variable Interest Entity (VIE), Gansu Qilianshan Pharmaceutical Co., Ltd. (Gansu QLS), and its subsidiaries via contractual arrangements. The company operates in pharmaceuticals (oxytetracycline, licorice, heparin), traditional Chinese medicine derivatives, sausage casings, and fertilizers.
Key Financial Metrics (Fiscal Year Ended Sept 30, 2024)
| Metric | 2024 (USD) | 2023 (USD) | Change |
|---|---|---|---|
| Net Revenue | $25,097,951 | $46,471,478 | (46.0%) |
| Gross Profit | $4,114,755 | $1,751,494 | +135.0% |
| Gross Margin | 16.4% | 3.8% | +12.6 pts |
| Net Loss (Consolidated) | $(1,517,161) | $(8,122,070) | (81.3%) |
| Net Loss Attributable to Shareholders | $(1,442,830) | $(7,780,620) | (81.5%) |
| EBITDA (Non-GAAP) | $(260,402) | $(6,859,030) | +96.2% |
| Cash and Cash Equivalents | $9,817,254 | $7,476,247 | +31.3% |
| Total Assets | $53,003,728 | $51,257,994 | +3.4% |
| Total Liabilities | $8,910,379 | $6,906,593 | +29.0% |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 46% primarily due to a $13.1 million decrease in Heparin and sausage casing sales (down 85%) and a $7.2 million decrease in Oxytetracycline and licorice sales (down 24%). The Heparin decline was driven by China's centralized procurement policy, which reduced prices by 50-70%, and a strategic decision to shut down production to limit losses.
- Margin Expansion: Despite lower revenue, gross margin improved significantly from 3.8% to 16.4%. This was driven by the discontinuation of loss-making Heparin production and improved margins in the licorice segment due to higher selling prices and cost adjustments.
- Loss Reduction: Net loss attributable to shareholders decreased by 81.5% to $1.44 million. This improvement was largely due to a reduction in investment losses from fair value changes in trading securities compared to the prior year.
- Share Consolidation: A 5-for-1 share consolidation effective June 21, 2024, was applied retroactively to all periods presented.
Guidance, Outlook, and Risks
- Capital Needs: Management estimates a need for at least $21.5 million over the next three years to fund expansion plans, including a new heparin facility in Chongqing and marketing efforts. The company intends to fund this via existing cash, operating cash flow, or additional equity/debt financing.
- Dividend Policy: The company does not intend to pay dividends in the foreseeable future, intending to retain earnings for operations and expansion.
- Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting related to the ability of in-house accounting professionals to generate US GAAP-compliant financial statements. Remediation plans include recruiting more qualified personnel and implementing training.
- VIE Structure Risks: The company relies on contractual arrangements to control its Chinese operating entities. If PRC authorities deem these arrangements invalid, the company could lose control of its operations, potentially rendering shares worthless.
- Regulatory Risks: Significant risks exist regarding PRC government intervention, cybersecurity regulations, and the Holding Foreign Companies Accountable Act (HFCA). While current auditors are subject to PCAOB inspection, future regulatory changes could impact listing status.
- Compliance Issues: The VIE has not fully complied with PRC regulations regarding social insurance and housing fund contributions for all employees, though management believes penalties are unlikely.
Investor Verification Checklist
- VIE Enforceability: Verify the legal status and enforceability of the contractual arrangements with Gansu QLS under current PRC law.
- Internal Control Remediation: Monitor progress on remedying the material weakness in internal controls over financial reporting.
- Capital Adequacy: Assess the company's ability to raise the estimated $21.5 million needed for future growth without excessive dilution.
- Heparin Segment Viability: Evaluate the long-term impact of China's centralized procurement policies on the heparin business and the success of the new Chongqing facility.
- Customer Concentration: Review the dependency on top customers (two customers represented 28% of sales in 2024) and the risk of losing them.
- Subsequent Events: Note the November 2024 transaction where the company issued ~70 million shares to acquire 100% of Patriton Limited (an AI/insurance tech entity), significantly altering the capital structure and business mix.